Equities research analysts at William Blair cut their FY2024 earnings per share estimates for shares of MarketAxess in a ...
William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...
Research analysts at William Blair dropped their FY2025 earnings estimates for shares of OneSpaWorld in a research report issued on Monday, January 13th. William Blair analyst S. Zackfia now ...
For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...
William Blair analyst Andrew Jeffrey initiated coverage of SoFi Technologies (SOFI) with an Outperform rating and no price target The firm ...
Enovix Corp (ENVX) stock saw a modest uptick, ending the day at $10.95 which represents a slight increase of $0.17 or 1.58% from the prior close of $10.78. The stock opened at $10.75 and touched a low ...
CHICAGO, January 07, 2025--(BUSINESS WIRE)--William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named Stewart ...
Portillo’s has never been one to follow the worn path in quick service. It hasn’t engaged in the “value wars” or materially ...
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...